Health CareHealth Care Equipment & Services
  • Price (NOK)28.10
  • Today's Change0.08 / 0.29%
  • Shares traded448.89k
  • 1 Year change-53.69%
  • Beta0.9474
Data delayed at least 15 minutes, as of Dec 13 2019 15:25 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-384.47m
  • Incorporated2009
  • Employees46.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Ultimovacs ASA0.00-48.50m1.03bn17.00--2.20-----2.36-2.360.0016.770.00----0.00-14.20---14.67--------------0.0073-------68.38------
XSpray Pharma AB (publ)198.00k-39.15m1.17bn13.00--4.49--5,913.49-2.75-2.750.013918.010.0008--0.067813,733.33-15.57---16.21-------19,774.27------0.0192---16.57---67.17------
Bergenbio ASA11.02m-192.77m1.18bn26.00--4.26--106.89-3.51-3.510.20054.530.0302--0.6252459,041.70-52.76---58.04-------1,749.71------0.0002-------5.24------
Hamlet Pharma AB0.00-16.21m1.19bn2.00--234.33-----0.5368-0.53680.000.16730.00----0.00-172.52---197.17--------------0.00-------4.93------
Q linea AB1.26m-148.76m1.21bn64.00--3.13--960.73-7.36-7.360.06117.230.0052--41.4624,641.51-61.61---68.98---1,615.70---11,850.92------0.002---28.93---89.09------
Infant Bacterial Therapeutics AB0.00-41.26m1.34bn8.00--2.68-----3.82-3.820.0047.920.00----0.00-7.56-17.29-7.67-18.00-------28,727.13----0.00---100.00---12.31------
Swedencare AB (publ)115.88m28.77m1.35bn33.0046.7811.2343.1511.621.901.907.647.910.92652.656.754,018,800.0023.0021.2726.4625.7374.2073.3324.8320.843.56146.310.00--15.9640.2537.06197.46----
IRLAB Therapeutics AB42.29k-84.93m1.38bn22.00--10.07--32,611.53-2.18-2.180.00113.520.0002--0.00771,760.00-43.52---47.27-------200,818.20-----454.460.00---83.49---31.79------
Cantargia AB0.00-98.41m1.45bn11.00--8.42-----1.48-1.480.002.450.00----0.00-49.98-49.51-56.66-57.92------------0.00-------51.30------
Genovis AB55.99m11.06m1.55bn23.00139.8044.07107.0227.620.18240.18240.92320.57871.24----2,912,799.0024.54-53.6331.34-73.8466.700.38719.76-68.35--15.570.1136--51.1731.1478.48---5.05--
Nordic Nanovector ASA0.00-384.47m1.61bn46.00--5.24-----7.23-,984.18----0.0251---100.00---14.96--48.77--
Bonesupport Holding AB127.23m-160.64m1.63bn80.00--10.59--12.83-3.23-3.232.563.090.44290.61926.101,838,486.00-55.92---68.17--85.47---126.26--2.68-2,303.330.0657---25.27---36.89------
Photocure ASA215.86m-22.68m1.82bn71.00--10.92--8.42-1.05-1.059.987.640.96991.1210.763,040,254.00-10.19-7.27-12.43-8.3590.9192.74-10.51-13.113.18--0.0455--20.2816.77-5.80--7.13--
Oasmia Pharmaceutical AB1.95m-202.54m1.82bn55.00--3.39--932.45-0.7895-0.78950.00741.250.00340.08320.803633,900.00-34.88-27.77-52.99-43.4457.47346.37-10,359.24-5,370.330.8504-9.030.2638---37.52101.23-71.08---19.54--
Orphazyme A/S0.00-383.97m1.84bn72.00--6.10-----14.31-14.310.0011.25------0.00-------------------66.070.0407-------81.93------
Orexo AB801.41m222.89m2.07bn130.009.473.208.162.586.546.5423.5519.350.60560.79312.866,463,566.0016.84-1.4426.36-2.1084.9077.8027.80-2.282.04--0.3419--21.6612.77494.40---43.66--
Data as of Dec 13 2019. Currency figures normalised to Nordic Nanovector ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

12.21%Per cent of shares held by top holders
HolderShares% Held
Folketrygdfondetas of 18 Jun 20193.51m5.31%
Nordea Investment Management AB (Norway)as of 31 Oct 20191.54m2.32%
KLP Kapitalforvaltning ASas of 29 Nov 20191.06m1.60%
Sissener ASas of 18 Jun 2019500.00k0.76%
Dimensional Fund Advisors LPas of 30 Sep 2019429.56k0.65%
Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016300.00k0.45%
Storebrand Asset Management ASas of 31 Aug 2019264.49k0.40%
DNB Asset Management ASas of 30 Sep 2019207.54k0.31%
Handelsbanken Kapitalforvaltning ASas of 30 Nov 2019188.88k0.29%
Xact Kapitalf�rvaltning ABas of 30 Nov 201979.74k0.12%
More ▼
Data from 31 Dec 2016 - 30 Nov 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.